Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry-Reference-Cited by-同舟云学术

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry

Published:2019-01-21 Issue:1 Volume:20 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Zurkova Monika, ,Kriegova Eva^ORCID,Kolek Vitezslav,Lostakova Vladimira,Sterclova Martina,Bartos Vladimir,Doubkova Martina,Binkova Ilona,Svoboda Michal,Strenkova Jana,Janotova Marketa,Plackova Martina,Lacina Ladislav,Rihak Vladimir,Petrik Frantisek,Lisa Pavlina,Bittenglova Radka,Tyl Richard,Ondrejka Gustav,Suldova Hana,Lnenicka Jaroslav,Psikalova Jana,Snizek Tomas,Homolka Jiri,Kralova Renata,Kervitzer Jan,Vasakova Martina,

Funder

Ministerstvo Zdravotnictví Ceské Republiky

Univerzita Palackého v Olomouci

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s12931-019-0977-2.pdf

Reference39 articles.

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: Idiopathic Pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

2. Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: executive summary. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:238–48.

3. Caminati A, Madotto F, Cesana G, Conti S, Harari S. Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev. 2015;24:436–44.

4. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2:566–72.